X4 Pharmaceuticals, Inc 8-K, filed Aug 25, 2025
X4 Pharmaceuticals, Inc (XFOR)
8-K
2025-08-25
For: 2025-08-22
View Original
Added on
April 12, 2026
About this 8-K
X4 Pharmaceuticals, Inc filed this 8-K on August 25, 2025, reporting on events of August 22, 2025.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| FORM | |||||
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 22, 2025
| (Exact name of registrant as specified in its charter) | ||||||||
| | ||||||||||||||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | ||||||||||
(857 ) 529-8300
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
_______________________________________________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | ||||
On August 22, 2025, David McGirr and R. Keith Woods resigned from the board of directors (the “Board”) of X4 Pharmaceuticals, Inc. (the “Company”), including all committees thereof, effective immediately. The resignations of Mr. McGirr and Mr. Woods from the Board are not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
In connection with the resignations of Messrs. McGirr and Woods, Michael Wyzga was appointed to serve as chair of the audit committee of the Board (the “Audit Committee”) and Francoise de Craecker and Gary Bridger were appointed to serve as members of the Audit Committee.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| X4 PHARMACEUTICALS, INC. | ||||||||||||||
| Date: August 25, 2025 | By: | /s/ David H. Kirske | ||||||||||||
| Name: | David H. Kirske | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||